Business
Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona. The presentation, titled “Pain Mitigation in Pancreatic Adeno
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona.","length":443,"tagName":"p"},{"type":"text","content":"The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” (Submission ID: 2249416), has been accepted as an oral podium presentation. Dr. Wilkirson will deliver a five-minute presentation followed by a two-minute question-and-answer session, highlighting the potential of Autonomix Medical’s minimally invasive transvascular RF energy-based approach to address chronic pain in pancreatic cancer patients.","length":498,"tagName":"p"},{"type":"text","content":"“Chronic pain is one of the most challenging complications faced by patients with pancreatic adenocarcinoma,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We are honored to share our long-term clinical analysis at SSO 2026, demonstrating how our transvascular RF approach may provide meaningful improvements in pain control and quality of life for patients facing this devastating disease.”","length":423,"tagName":"p"},{"type":"text","content":"The SSO Annual Meeting convenes leading surgical oncologists, researchers and healthcare professionals to showcase advances in surgical oncology and emerging clinical technologies. For more information, please visit the conference website here.","length":244,"tagName":"p"},{"type":"text","content":"...